Hims & Hers can't sell off-brand Ozempic forever. But it can still sell these weight loss drugs
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Hims & Hers will stop selling some weight loss drugs — and the stock plummets 27%
Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Hims Stock Drops on Uncertainty About Weight-Loss Business
Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...
Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins
Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Hims & Hers Health (NYSE:HIMS) Craters With Weight Loss Drug Issues
It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...
Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight ...